Australia - English - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - carmustine, quantity: 100 mg - injection, powder for - excipient ingredients: - indications as at 16 december 1985: carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma. 2. multiple myeloma: in combination with prednisone. 3. hodgkin's disease: as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkins lymphomas: as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - carmustine (unii: u68wg3173y) (carmustine - unii:u68wg3173y) - carmustine 100 mg in 30 ml - bicnu® (carmustine for injection) is indicated as palliative therapy as a single agent or in established combination therapy in the following: - brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - multiple myeloma in combination with prednisone. - relapsed or refractory hodgkin's lymphoma in combination with other approved drugs. - relapsed or refractory non-hodgkin's lymphomas in combination with other approved drugs. bicnu is contraindicated in patients with previous hypersensitivity to bicnu or its components. risk summary bicnu (carmustine for injection) can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see clinical pharmacology (12.1) ] and findings in animals [see data] . limited available data with bicnu use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. carmustine was embryotoxic in rats and rabbits and teratogenic in rats (thoracoabd

Canada - English - Health Canada

marcan pharmaceuticals inc - carmustine - powder for solution - 100mg - carmustine 100mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

carmustine -

New Zealand - English - Medsafe (Medicines Safety Authority)

luminarie group limited - carmustine 100mg - solution for injection - 100 mg - active: carmustine 100mg excipient: ethanol - bicnu is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in patients with the following malignancies:- 1. primary brain tumours - glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumours. 2. multiple myeloma - in combination with prednisone. 3. menigeal leukaemia - bicnu should be used in patients who have not responded to intrathecal administrations of methotrexate 4. hodgkin's disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 5. malignant melanoma (disseminated) - bicnu should be used in combination with other active chemotherapeutic agents. 6. non-hodgkin's lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy 7. other solid tumours; gastointestinal carcinoma, breast carcinoma - bicnu has been used in combination with other therapeutic agents only after other conventional methods have failed.

Singapore - English - HSA (Health Sciences Authority)

advagen pte. ltd. - carmustine - injection, powder, for solution - carmustine 100 mg/ vial

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - carmustine - pdr+solv for soln for inj - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - carmustine - pdr+solv for soln for inj - 100 milligram

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bm_squib -